PPAT and cancer: As such a target, we chose phosphoribosyl pyrophosphate amidotransferase (PPAT), a rate-limiting enzyme in the de novo nucleotide synthesis pathway, given that its expression is most correlated among all metabolic enzymes with poor prognosis in various human cancers and that its depletion markedly inhibits tumor growth (Kodama et al., 2020).